Loading
A phase 1/2 trial of CRC01, Fludarabine, Cyclophosphamide in diffuse large b-cell lymphoma and follicular lymphoma, run by Curocell Inc., now recruiting.
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients is a phase 1/2 interventional study registered as NCT04836507 by Curocell Inc., with 91 participants planned, started 2021-03-02 and due to reach its primary completion in 2030-08-15. Interventions recorded: CRC01, Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal Large B-Cell Lymphoma (PMBCL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide, Diffuse large B-cell lymphoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Follicular lymphoma, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/